clinical trial · NCT06864585
A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan
Pfizer·—·not yet recruiting·n = 59
Infectious DiseasesAvibactam sodium/Ceftazidime hydrate
brief summary
The purpose of this study is to learn about the safety and how effective is Zavicefta under actual clinical practice in Japan. Zavicefta is a combination of Avibactam sodium and Ceftazidime hydrate. This study is seeking for patients with: * sepsis (A very serious infection in your blood caused by germ (a bacteria)) or * renal impairment (loss of kidney function) who are administrated with Zavicefta for the first time. Subjects will take part in this study from the start date of receiving Zavicefta (Day 1) to Day 28.
started
Sep 15, 2026
primary completion
Mar 30, 2029
completion
Mar 30, 2029
last updated
Apr 20, 2026
official title
Zavicefta Combination for Intravenous Infusion Special Investigation - Surveillance on Patients With Sepsis or Renal Impairment (Creatinine Clearance ≤ 50 mL/Min) -
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol